Form D · Biotechnology
Antares Therapeutics, Inc.
Boston, MA · CIK 0002059043
Offering snapshot reported May 15, 2025 · SEC filing
- Reported sold
- $30M Offering amount: $137M
- Investors reported
- 35 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 1, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2025 | Initial | $30,000,000 | No comparison | 35 | SEC filing |
| Mar 12, 2025 | Initial | $40,000,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-546316
Source: Form D, filed May 15, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Albers | Director |
| Shelley Chu | Director |
| Andrew Fedder | Executive |
| Keith Flaherty | Director |
| Jean Francois Formela | Director |
| Adam Friedman | Director, Executive |
| Menelas N. Pangalos | Director |
| Brian Piper | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Winthrop Square, Suite 400
Boston, MA, 02110
Boston, MA, 02110